For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Aveo Pharmaceuticals, Inc.

USPTO Granted Patents = 40

CIPO Patents = 14

EPO Patents = 13

Trademarks = 14

Forward Citations = 163

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

83 inventors (with patents filed for the assignee):

William M Winston, Jr (28 out of 28 patents)

Jeno Gyuris (28 out of 28 patents)

Lyne Breault (17 out of 17 patents)

4. Solly Weiler (14 out of 14 patents)

5. Ting Chen (13 out of 79 patents)

6. Jie Lin (12 out of 13 patents)

7. May Han (11 out of 11 patents)

8. Kristan Meetze (10 out of 12 patents)

9. Lorena Lerner (9 out of 9 patents)

10. S Kirk Wright (9 out of 9 patents)

11. Bijan Etemad-Gilbertson (9 out of 10 patents)

12. Christine Knuehl (9 out of 9 patents)

13. Sandra Abbott (8 out of 8 patents)

14. Sylvie Vincent (8 out of 8 patents)

15. Steve Bottega (8 out of 8 patents)

40 patents: Sort by Forward Citations

1. 12338282 - Anti-Notch3 antibody (2025-06-24),

2. 12269877 - Anti-notch3 antibodies (2025-04-08),

3. 12258391 - Anti-GDF-15 antibodies (2025-03-25),

4. 11897948 - Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator (2024-02-13),

5. 11725047 - Anti-GDF-15 antibodies (2023-08-15),

6. 11680108 - Anti-ErbB3 antibodies (2023-06-20),

7. 11504365 - Use of tivozanib to treat subjects with refractory cancer (2022-11-22),

8. 11142573 - Anti-Notch3 antibody (2021-10-12),

9. 10745476 - Anti-NOTCH3 antibodies (2020-08-18),

10. 10597444 - Anti-GDF15 antibodies (2020-03-24),

11. 10494441 - Anti-ERBB3 antibodies (2019-12-03),

12. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),

13. 9879083 - Anti-Notch3 antibodies (2018-01-30),

14. 9828635 - Predicting tumor response to anti-ERBB3 antibodies (2017-11-28),

15. 9725505 - Methods of treatment using anti-GDF15 antibodies (2017-08-08),

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing targeted cancer therapeutics. They focus on advancing their lead product candidate, tivozanib, for the treatment of various forms of cancer. AVEO is committed to improving the lives of patients and providing effective treatment options for oncology challenges.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

40 Patents

#61 in Boston, MA

#485 in Massachusetts

#8,341 in US

#16,536 in the World

Boston, MA, United States of America

Aveo Pharmaceuticals, Inc.

Forward Citations = 163

83 inventors:

William M Winston, Jr (28 out of 28 patents)

Jeno Gyuris (28 out of 28 patents)

Lyne Breault (17 out of 17 patents)

4. Solly Weiler (14 out of 14 patents)

5. Ting Chen (13 out of 79 patents)

Please report any incorrect information to support@idiyas.com

Loading…